Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection

JAMA

Volumn 305, Issue 14, 2011, Pages 1441-1449

  Tronstein, Elizabeth ^a   Johnston, Christine ^a,b   Huang, Meei Li ^a,b   Selke, Stacy ^a   Magaret, Amalia ^a,b   Warren, Terri ^c   Corey, Lawrence ^a,b   Wald, Anna ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Westover Heights Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYMPTOMATOLOGY; VIRUS DETECTION; VIRUS SHEDDING; VIRUS TRANSMISSION;

EID: 79953848750     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.420     Document Type: Article

References (34)

1. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest. 1997;99(5):1092-1097. (Pubitemid 27123647)
2. Mertz KJ, Trees D, Levine WC, et al; Genital Ulcer Disease Surveillance Group. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. J Infect Dis. 1998;178(6): 1795-1798. (Pubitemid 28558157)
3. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ. 2008;86(10):805-812.
4. Centers for Disease Control and Prevention (CDC). Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years-United States, 2005-2008. MMWR Morb Mortal Wkly Rep. 2010;59(15): 456-459.
5. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med. 2000; 342(12):844-850. (Pubitemid 30165207)
6. Mertz GJ. Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission. J Infect Dis. 2008;198(8):1098- 1100.
7. Schiffer JT, Abu-Raddad L, Mark KE, et al. Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med. 2009;1(7):7ra16.
8. Magaret AS, Johnston C, Wald A. Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling. Sex Transm Infect. 2009;85(4):270-275.
9. Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis. 2008;198 (8):1141-1149.
10. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med. 1996; 124(1 pt 1):8-15. (Pubitemid 26019618)
11. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol. 1988;26(4): 662-667. (Pubitemid 18087189)
12. Ryncarz AJ, Goddard J, Wald A, Huang ML, Roizman B, Corey L. Development of a highthroughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol. 1999;37(6):1941-1947. (Pubitemid 29235250)
13. Magaret AS, Wald A, Huang ML, Selke S, Corey L. Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa. J Clin Microbiol. 2007;45(5):1618-1620. (Pubitemid 46762423)
14. Corey L, Holmes KK. Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention. Ann Intern Med. 1983;98(6):973-983. (Pubitemid 13053414)
15. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994;121(11):847-854.
16. Phipps WSM, Saracino M, Magaret A, et al. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J Infect Dis. 2011; 203(2):180-187.
17. Diggle P. Analysis of Longitudinal Data. 2nd ed. New York, NY: Oxford University Press; 2002.
18. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992;116(3):197-202.
19. Zhu J, Koelle DM, Cao J, et al. Virus-specific CD8+T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med. 2007;204(3):595-603. (Pubitemid 46457082)
20. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. 1997;337(16):1105-1111. (Pubitemid 27444100)
21. Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ. 1994;309(6965):1325-1329.
22. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med. 1995; 333(12):770-775.
23. Sucato G, Wald A, Wakabayashi E, Vieira J, Corey L. Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region. J Infect Dis. 1998;177(4):1069-1072. (Pubitemid 28155164)
24. Leone P, AbudaluM,Mitha E, Gani M, Zhou W, Hamed K. One-day famciclovir vs placebo in patientinitiated episodic treatment of recurrent genital herpes in immunocompetent black patients. Curr Med Res Opin. 2010;26(3):653-661.
25. Bochud PY, Magaret AS, Koelle DM, Aderem A, Wald A. Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus type 2 infection. J Infect Dis. 2007;196(4):505-509. (Pubitemid 47206095)
26. Casrouge A, Zhang SY, Eidenschenk C, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science. 2006;314(5797):308-312. (Pubitemid 44571977)
27. Celum C, Wald A, Lingappa JR, et al; Partners in Prevention HSV/HIV Transmission Study Team. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010; 362(5):427-439.
28. Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of HIV-1 plasma RNA reductions on heterosexual HIV-1 transmission risk. PLoS One. 2010;5(9):e12598. doi:12510.11371/journal.pone .0012598.
29. Cone RW, Hobson AC, Brown Z, et al. Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women. JAMA. 1994;272(10):792-796. (Pubitemid 24275692)
30. Corey L, Wald A, Patel R, et al; Valacyclovir HSV Transmission Study Group. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350(1):11-20. (Pubitemid 38032179)
31. Melville J, Sniffen S, Crosby R, et al. Psychosocial impact of serological diagnosis of herpes simplex virus type 2: a qualitative assessment. Sex Transm Infect. 2003;79(4):280-285. (Pubitemid 37026343)
32. Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA. 2001; 285(24):3100-3106. (Pubitemid 32578207)
33. Wald A, Krantz E, Selke S, Lairson E, Morrow RA, Zeh J. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis. 2006;194(1):42-52.
34. Guerry SL, Bauer HM, Klausner JD, et al. Recommendations for the selective use of herpes simplex virus type 2 serological tests. Clin Infect Dis. 2005; 40(1):38-45. (Pubitemid 40053457)